EUVIMEDEUVIMED entdecken
Kommentar

Mazdutide and Orforglipron—New Evidence in Obesity and Diabetes

Kishore M Gadde, Jonanne Talebloo, Steven B Heymsfield

JAMA · 04.08.2026 · 336 (5) · 374

DOI: 10.1001/jama.2026.10443 ↗

Kurz gefasst

Kommentar in der Zeitschrift JAMA, erschienen am 04.08.2026. Verfasst von Kishore M Gadde und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastrointestinal Surgery, Department of Surgery, University of California Irvine School of Medicine, Orange. Die Arbeit nennt 15 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Division of Gastrointestinal Surgery, Department of Surgery, University of California Irvine School of Medicine, Orange.
  • Division of Gastroenterology, Department of Medicine, University of California Irvine School of Medicine, Orange.
  • Pennington Biomedical Research Center, Baton Rouge, Louisiana.

Zitieren

APA

Gadde, K. M., Talebloo, J., & Heymsfield, S. B. (2026). Mazdutide and Orforglipron—New Evidence in Obesity and Diabetes. JAMA, 336(5), 374. https://doi.org/10.1001/jama.2026.10443

Vancouver

Gadde KM, Talebloo J, Heymsfield SB. Mazdutide and Orforglipron—New Evidence in Obesity and Diabetes. JAMA. 2026;336(5):374. doi:10.1001/jama.2026.10443

BibTeX
@article{Gadde2026,
  author = {Gadde, Kishore M and Talebloo, Jonanne and Heymsfield, Steven B},
  title = {Mazdutide and Orforglipron—New Evidence in Obesity and Diabetes},
  journal = {JAMA},
  year = {2026},
  volume = {336},
  number = {5},
  pages = {374},
  doi = {10.1001/jama.2026.10443}
}
Kostenlos starten →